Journal of pain and symptom management · 2025
Pericapsular Nerve Group Phenol Neurolysis for Refractory Metastatic Hip Pain: A Case Series.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pérez-Moreno Diana, Forero Mauricio, Juárez-Lemus Ángel M, Mora-Arteaga Javier
Аннотация
BACKGROUND: Cancer-related hip pain due to tumor infiltration is challenging, especially in patients with limited life expectancy. While ultrasound-guided pericapsular nerve group (PENG) phenol neurolysis has been reported in isolated cases, systematic evidence on effectiveness and safety remains limited.
METHODS: We conducted a prospective case series of three patients with refractory metastatic hip pain who underwent ultrasound-guided PENG phenol neurolysis using 10 mL of 10% nonglycerinated phenol, with six-week follow-up. Assessments were performed at baseline, 10 minutes, 24 hours, and Weeks 1, 2, 4, and 6 using validated measures: pain intensity (Visual Analog Scale [VAS]), neuropathic pain (Douleur Neuropathique 4 [DN4]), opioid consumption (oral morphine milligram equivalents [MME]), and function (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]). Adverse events were predefined as new motor deficit, persistent sensory loss, infection, bleeding, or vasovagal reaction, and were monitored with serial neurochecks for 4 hours postprocedure and at each follow-up through Week 6.
RESULTS: All patients-bedbound at baseline with VAS 10/10-experienced rapid and marked analgesia, with VAS scores of 1-2 within 10 minutes and sustained relief through six weeks. DN4 scores fell below the diagnostic threshold (≤3) in all cases. Daily opioid consumption decreased by 47%-77%, and all patients achieved assisted ambulation within 24 hours. No motor weakness occurred; the only adverse event was mild, transient anterior-hip hypoesthesia.
CONCLUSION: Ultrasound-guided PENG phenol neurolysis (10% phenol) may be a valuable motor-sparing option for refractory cancer-related hip pain in selected palliative care patients. These preliminary findings warrant evaluation in larger, controlled studies.
METHODS: We conducted a prospective case series of three patients with refractory metastatic hip pain who underwent ultrasound-guided PENG phenol neurolysis using 10 mL of 10% nonglycerinated phenol, with six-week follow-up. Assessments were performed at baseline, 10 minutes, 24 hours, and Weeks 1, 2, 4, and 6 using validated measures: pain intensity (Visual Analog Scale [VAS]), neuropathic pain (Douleur Neuropathique 4 [DN4]), opioid consumption (oral morphine milligram equivalents [MME]), and function (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]). Adverse events were predefined as new motor deficit, persistent sensory loss, infection, bleeding, or vasovagal reaction, and were monitored with serial neurochecks for 4 hours postprocedure and at each follow-up through Week 6.
RESULTS: All patients-bedbound at baseline with VAS 10/10-experienced rapid and marked analgesia, with VAS scores of 1-2 within 10 minutes and sustained relief through six weeks. DN4 scores fell below the diagnostic threshold (≤3) in all cases. Daily opioid consumption decreased by 47%-77%, and all patients achieved assisted ambulation within 24 hours. No motor weakness occurred; the only adverse event was mild, transient anterior-hip hypoesthesia.
CONCLUSION: Ultrasound-guided PENG phenol neurolysis (10% phenol) may be a valuable motor-sparing option for refractory cancer-related hip pain in selected palliative care patients. These preliminary findings warrant evaluation in larger, controlled studies.